| 2025-05-01 | -0.41 % |
|
| 2025-04-29 | +0.98 % |
|
| 2025-04-28 | -0.66 % |
|
| 2025-04-24 | +6.63 % |
|
| 2025-04-23 | -0.2 % |
|
| 2025-04-21 | -3.26 % |
|
| 2025-04-01 | -0.84 % |
|
| 2025-03-28 | -0.39 % |
|
| 2025-03-27 | +0.14 % |
|
| 2025-03-21 | -0.69 % |
|
| 2025-03-19 | +0.8 % |
|
| 2025-03-10 | -2.56 % |
|
| 2025-03-07 | -2.05 % |
|
| 2025-03-05 | +2.06 % |
|
| 2025-02-28 | +0.31 % |
|
| 2025-02-27 | -0.78 % |
|
| 2025-02-25 | -1.8 % |
|
| 2025-02-18 | -0.68 % |
|
| 2025-02-14 | +0.25 % |
|
| 2025-02-12 | +6.92 % |
|
| 2025-02-11 | -0.27 % |
|
| 2025-02-10 | +1.07 % |
|
| 2025-02-07 | -0.9 % |
|
| 2025-02-04 | -0.07 % |
|
| 2025-02-03 | -1.48 % |
|
| 2025-01-23 | -0.16 % |
|
| 2025-01-21 | +0.27 % |
|
| 2025-01-16 | -0.6 % |
|
| 2025-01-14 | -0.07 % |
|
| 2025-01-13 | -3.17 % |
|
| 2025-01-06 | -0.5 % |
|
| 2024-12-31 | -0.28 % |
|
| 2024-12-17 | +0.28 % |
|
| 2024-12-16 | +0.8 % |
|
| 2024-12-12 | +0.22 % |
|
| 2024-12-10 | +3.51 % |
|
| 2024-12-06 | -1.24 % |
|
| 2024-12-05 | -2.39 % |
|
| 2024-12-04 | +5.7 % |
|
| 2024-12-03 | -0.47 % |
|
| 2024-12-02 | -1.15 % |
|
| 2024-11-29 | -1 % |
|
| 2024-11-27 | +0.73 % |
|
| 2024-11-26 | +0.39 % |
|
| 2024-11-25 | +1.12 % |
|
| 2024-11-22 | +0.14 % |
|
| 2024-11-21 | +1.21 % |
|
| 2024-11-20 | -0.94 % |
|
| 2024-11-19 | +0.44 % |
|
| 2024-11-18 | +3.14 % |
|
| 2024-11-13 | +1.08 % |
|
| 2024-11-07 | +0.14 % |
- Edwards Lifesciences (EW) stock rose by 0.14% amid mixed activity from institutional investors, with Robeco Institutional Asset Management significantly reducing its stake while others increased theirs, suggesting investor confidence in the company's long-term potential despite recent fluctuations.
The stock increase may be attributed to a combination of factors, including positive earnings results that met consensus estimates, growth in revenue compared to the previous year, and responses from analysts indicating a hold or buy rating, reflecting general optimism about the company's future prospects.
- Edwards Lifesciences (EW) stock was up 0.14% despite facing a class action lawsuit related to disappointing revenue guidance and performance for its TAVR platform, potentially indicating market optimism about recovery or interest in the company following recent negative news.
The stock may have gone up due to factors such as market recovery expectations, investor confidence in long-term growth, or speculative buying amidst the legal activity, despite the recent past decline related to the company's financial performance.
- The article discusses an investigation into Edwards Lifesciences Corporation regarding potential securities law violations, following a significant drop in their stock price due to disappointing financial results and reduced revenue guidance for their TAVR product, but despite this, the stock saw a slight increase of 0.14% last night.
The increase in Edwards Lifesciences (EW) stock may stem from investor reactions to potential recovery opportunities or market adjustments following the previous decline, as well as speculation regarding future performance and the overall health of the healthcare sector.
- Edwards Lifesciences (NYSE:EW) stock rose 0.14% following a significant insider sale of shares, but the overall market sentiment can be attributed to recent quarterly earnings results that met expectations and positive analyst upgrades despite some price target reductions.
- Edwards Lifesciences (EW) stock increased by 0.14% amid a class action lawsuit reminder for investors who suffered losses between February and July 2024, following a significant decline in stock price after disappointing fiscal results and lowered projections for its Transcatheter Aortic Valve Replacement (TAVR) platform.
The stock may have gone up due to short-term market recovery or investor speculation despite the ongoing legal issues and previous financial setbacks.
|
